TCTR20190118012已完成2 期
Comparison of glucose control by added liraglutide to only insulin infusion in DM patient undergoing cardiac surgery: A randomized-controlled trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Diabetic patients who undergo coronary artery bypass graft operation or valvular surgery that use cardiopulmonary bypass
排除标准
- •1.History allergy to Liraglutide or insulin drug
- •2.Patients have contraindication for using Liraglutide drug such as Medullary thyroid carcinoma, Multiple Endocrine Neoplasia Syndrome type2(MEN type2), Thyroid C-cell tumors and Pancreatitis
- •3.Patients have Diabetic Ketoacidosis condition during reseach progression.
- •4.Patientds have allergic reaction to liraglutide drug during reseach progression.
研究者
相似试验
终止
4 期
ovel approaches to manage glucocorticoid-induced diabetes in hospital inpatientsglucocorticoid-induced or -exacerbated diabetesMetabolic and Endocrine - DiabetesACTRN12615000333516Alfred Hospital30
进行中（未招募）
1 期
The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitusGestational diabetes mellitus Non-alcoholic fatty liver diseaseMedDRA version: 20.0 Level: LLT Classification code 10018210 Term: Gestational diabetes mellitus System Organ Class: 100000004868MedDRA version: 20.1 Level: PT Classification code 10029530 Term: Non-alcoholic fatty liver System Organ Class: 10019805 - Hepatobiliary disordersEUCTR2012-001371-37-DKDr. med. Tina Vilsbøll160
进行中（未招募）
不适用
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension period followed by an additional 38-week, non-randomised extension period followed by an additional 38-week, non-randomised extension period.type 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-006092-21-ATovo Nordisk a/s723
进行中（未招募）
1 期
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension periodEUCTR2006-006092-21-FRovo Nordisk a/s
进行中（未招募）
不适用
Effect on glycaemic control of liraglutide or exenatide added to metformin, sulphonylurea or a combination of both in subjects with type 2 diabetesA 26-week randomised, open-label, active comparator, 2-armed, parallel-group, multi-centre, multi-national trial with a 14 week non-randomised extension period followed by an additional 38-week, non-randomised extension period.type 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-006092-21-DEovo Nordisk A/S723